{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:56:38Z","timestamp":1790218598635,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ijid.2022.09.013","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T12:38:04Z","timestamp":1663850284000},"page":"118-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4511-9430","authenticated-orcid":false,"given":"Marcela","family":"Krutova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Kuijper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.09.013_bib0001","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1128\/AAC.00090-08","article-title":"Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease","volume":"52","author":"Al-Nassir","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.09.013_bib0002","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/cis453","article-title":"Fidaxomicin inhibits spore production in Clostridium difficile","volume":"55","author":"Babakhani","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0003","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1099\/jmm.0.029470-0","article-title":"Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile","volume":"60","author":"Babakhani","year":"2011","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijid.2022.09.013_bib0004","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.cmi.2018.12.024","article-title":"Toxigenic Clostridium difficile carriage in general practice: results of a laboratory-based cohort study","volume":"25","author":"Barbut","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.09.013_bib0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jhin.2015.01.015","article-title":"Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin","volume":"90","author":"Biswas","year":"2015","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijid.2022.09.013_bib0006","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/jac\/dkab097","article-title":"Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile","volume":"76","author":"Boekhoud","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.09.013_bib0007","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gut.27.10.1169","article-title":"Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile","volume":"27","author":"Bolton","year":"1986","journal-title":"Gut"},{"key":"10.1016\/j.ijid.2022.09.013_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161200","article-title":"Association of fidaxomicin with C. difficile spores: effects of persistence on subsequent spore recovery, outgrowth and toxin production","volume":"11","author":"Chilton","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2022.09.013_bib0009","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/cid\/ciaa484","article-title":"Impact of revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America clinical practice guidelines on the treatment of Clostridium difficile infections in the United States","volume":"72","author":"Clancy","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0010","series-title":"Performance Standards for antimicrobial Susceptibility testing. M100","year":"2020"},{"key":"10.1016\/j.ijid.2022.09.013_bib0011","doi-asserted-by":"crossref","first-page":"ofaa362","DOI":"10.1093\/ofid\/ofaa362","article-title":"An analysis of Clostridium difficile environmental contamination during and after treatment for C difficile infection","volume":"7","author":"Davies","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0012","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1126\/science.1110591","article-title":"Diversity of the human intestinal microbial flora","volume":"308","author":"Eckburg","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ijid.2022.09.013_bib0013","unstructured":"European committee on antimicrobial susceptibility testing (EUCAST), Clinical breakpoints - breakpoints and guidance, 2022, http:\/\/www.eucast.org\/clinical_breakpoints. (accessed 3 March 2022)."},{"key":"10.1016\/j.ijid.2022.09.013_bib0015","unstructured":"European Medicines Agency, Dificlir: EPAR - Porduct Information, 2022, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dificlir-epar-product-information_en.pdf, (accessed 3 March 2022)."},{"key":"10.1016\/j.ijid.2022.09.013_bib0014","unstructured":"European Medicines Agency, Vancomycin Article-31 referral - Annex III. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/vancomycin-article-31-referral-annex-iii_en.pdf, 2017 (accessed 3 March 2022)."},{"key":"10.1016\/j.ijid.2022.09.013_bib0016","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/AAC.48.12.4898-4902.2004","article-title":"In vitro activities of OPT-80 and comparator drugs against intestinal bacteria","volume":"48","author":"Finegold","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.09.013_bib0017","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.cmi.2014.09.017","volume":"21","author":"Freeman","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.09.013_bib0018","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10096-019-03708-7","article-title":"Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study","volume":"39","author":"Freeman","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2334-14-29","article-title":"Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin\/tazobactam","volume":"14","author":"Garneau","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0020","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1128\/AAC.00625-11","article-title":"Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection","volume":"55","author":"Goldstein","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.09.013_bib0021","doi-asserted-by":"crossref","first-page":"ofab365","DOI":"10.1093\/ofid\/ofab365","article-title":"Reduced susceptibility to metronidazole is associated with initial clinical failure in Clostridioides difficile infection","volume":"8","author":"Gonzales-Luna","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0022","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.anaerobe.2017.02.006","article-title":"Comparison of Clostridium difficile minimum inhibitory concentrations obtained using agar dilution vs broth microdilution methods","volume":"44","author":"Hastey","year":"2017","journal-title":"Anaerobe"},{"key":"10.1016\/j.ijid.2022.09.013_bib0023","doi-asserted-by":"crossref","first-page":"O1067","DOI":"10.1111\/1469-0691.12758","article-title":"Diarrhoea in general practice: when should a Clostridium difficile infection be considered? Results of a nested case-control study","volume":"20","author":"Hensgens","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.09.013_bib0024","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0025","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/jac\/dkaa118","article-title":"Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017","volume":"75","author":"Karlowsky","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.09.013_bib0026","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijid.2022.09.013_bib0027","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.cmi.2022.03.001","article-title":"How to: Clostridioides difficile infection in children","volume":"28","author":"Krutova","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.09.013_bib0028","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003088-199936050-00004","article-title":"Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials","volume":"36","author":"Lamp","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2022.09.013_bib0029","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/cid\/cis338","article-title":"Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI","volume":"55","author":"Louie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-021-03986-2","article-title":"Unravelling the collateral damage of antibiotics on gut bacteria","volume":"599","author":"Maier","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2022.09.013_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.17597","article-title":"Incidence and outcomes associated with Clostridium difficile infections: a systematic review and meta-analysis","volume":"3","author":"Marra","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijid.2022.09.013_bib0032","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0033","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1093\/cid\/cis440","article-title":"Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"55","author":"Nerandzic","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0034","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1128\/AAC.00079-13","article-title":"Effects of antibiotics on bacterial species composition and metabolic activities in chemostats containing defined populations of human gut microorganisms","volume":"57","author":"Newton","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.09.013_bib0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000104471","article-title":"Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile","volume":"53","author":"Odenholt","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijid.2022.09.013_bib0036","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s10096-021-04311-5","article-title":"Antimicrobial resistance in Clostridioides difficile","volume":"40","author":"O'Grady","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0037","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.3389\/fmicb.2017.02584","article-title":"Antibiotic resistance and toxin production of Clostridium difficile isolates from the hospitalized patients in a Large Hospital in Florida","volume":"8","author":"Peng","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijid.2022.09.013_bib0038","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1399-3062.2009.00426.x","article-title":"Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract","volume":"11","author":"Pogue","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0039","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2020.10.046","article-title":"Plasmid acquisition alters vancomycin susceptibility in Clostridioides difficile","volume":"160","author":"Pu","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijid.2022.09.013_bib0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0378-1097(03)00513-5","article-title":"Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract","volume":"225","author":"Rafii","year":"2003","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.ijid.2022.09.013_bib0041","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.anaerobe.2019.102072","article-title":"Increasing antibiotic resistance in Clostridioides difficile: a systematic review and meta-analysis","volume":"58","author":"Saha","year":"2019","journal-title":"Anaerobe"},{"key":"10.1016\/j.ijid.2022.09.013_bib0042","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jac\/dky375","article-title":"Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB","volume":"74","author":"Schwanbeck","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.09.013_bib0043","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1093\/cid\/cis337","article-title":"Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection","volume":"55","author":"Sears","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0044","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13756-020-00815-5","article-title":"Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis","volume":"9","author":"Sholeh","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijid.2022.09.013_bib0045","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s41380-018-0086-5","article-title":"Gut microbiota modulate neurobehavior through changes in brain insulin sensitivity and metabolism","volume":"23","author":"Soto","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.ijid.2022.09.013_bib0046","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/cid\/ciz871","article-title":"Use of oral vancomycin for Clostridioides difficile infection and the risk of vancomycin-resistant enterococci","volume":"71","author":"Stevens","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0047","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijantimicag.2015.03.016","article-title":"Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection","volume":"46","author":"Thabit","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2022.09.013_bib0048","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/cid\/ciab473","article-title":"Impact of oral metronidazole, vancomycin, and fidaxomicin on host shedding and environmental contamination with Clostridioides difficile","volume":"74","author":"Turner","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.013_bib0049","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.09.013_bib0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/PPA.S229539","article-title":"Patient experiences with Clostridioides difficile infection: results of a Canada-wide survey","volume":"14","author":"Vent-Schmidt","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.ijid.2022.09.013_bib0051","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jhep.2013.11.034","article-title":"Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity","volume":"60","author":"Vrieze","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2022.09.013_bib0052","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00585-21","article-title":"The integrity of heme is essential for reproducible detection of metronidazole-resistant Clostridioides difficile by agar dilution susceptibility tests","volume":"59","author":"Wu","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2022.09.013_bib0053","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jiac.2017.08.004","article-title":"An extremely high bioavailability of orally administered vancomycin in a patient with severe colitis and renal insufficiency","volume":"23","author":"Yamazaki","year":"2017","journal-title":"J Infect Chemother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222005124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222005124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:10:25Z","timestamp":1761120625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222005124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":53,"alternative-id":["S1201971222005124"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.09.013","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}